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Introduction and objective: Currently, carbon nanostructures are vastly explored materials 
with potential for future employment in biomedicine. The possibility of employment of diamond 
nanoparticles (DN), graphene oxide (GO) or graphite nanoparticles (GN) for in vivo applications 
raises a question of their safety. Even though they do not induce a direct toxic effect, due to their 
unique properties, they can still interact with molecular pathways. The objective of this study 
was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, 
namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver.
Methods: Dose-dependent effect of the DN, GO and GN nanostructures on the catalytic activity 
of CYPs was examined using microsome-based model. Cytotoxicity of DN, GO and GN, as well 
as the influence of the nanostructures on mRNA expression of CYP genes and CYP-associated 
receptor genes were studied in vitro using HepG2 and HepaRG cell lines.
Results: All three nanostructures interacted with the CYP enzymes and inhibited their cata-
lytic activity in microsomal-based models. CYP gene expression at the mRNA level was also 
downregulated in HepG2 and HepaRG cell lines. Among the three nanostructures, GO showed 
the most significant influence on the enzymes, while DN was the most inert. 
Conclusion: Our findings revealed that DN, GO and GN might interfere with xenobiotic and 
drug metabolism in the liver by interactions with CYP isoenzymes responsible for the pro-
cess. Such results should be considered if DN, GO and GN are used in medical applications.
Keywords: carbon nanostructures, nanoparticles, cytochrome P450, microsomes, liver
Introduction
Recent advances in nanotechnology are strongly focused on the application of 
nanoparticles and nanomaterials in biotechnology and biomedical-related fields. 
The possibility of using carbon nanostructures as a component of drug delivery sys-
tems,1 diagnostic tools and biosensors2,3 or anticancer therapies4–6 is considered to be 
the future; however, at the same time, it raises a question of safety and toxicity of 
the materials.7 They are tested for biocompatibility when intended for contact with 
human body, both externally, for example, as a dressing,8 and internally, for example, 
for the delivery of imaging contrast9–11 or active compounds.12 It has been shown 
that regardless of administration route for internal applications, nanoparticles can 
be transported with blood to tissues where they might be deposited for a long time, 
sometimes binding proteins and changing their function. The major site of nanoparticle 
deposition is the liver;13 therefore, detailed studies on the impact of nanoparticles on 
liver functions are necessary. The liver is a major organ responsible for the metabo-
lism and biotransformation of xenobiotics, including drugs; so, possible interactions 
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with liver enzymes should be considered, especially when 
drugs are co-administrated with nanoparticles. Even though 
it was shown that carbon nanoparticles did not induce direct 
toxic effects on the liver tissue,14 there is a possibility that 
interaction with enzymes responsible for metabolism might 
change the effectiveness of a drug.
The major enzymes responsible for the metabolism of 
xenobiotics are members of the cytochrome P450 (CYP) 
family. CYP isoforms are catalysts for Phase I metabolism, 
where the oxygen atom is built into a parent compound, 
making the compound more hydrophilic.15 Usually, toxins are 
detoxified and drugs can be transformed into an active form; 
however, some cytochromes are engaged in the metabolic 
activation of carcinogens. The biotransformation reactions 
take place in the active site located in a pocket of the CYP 
enzyme. The key factor for CYP functioning is proper elec-
tron transfer from a flavoprotein donor, which determines 
the catalytic activity within the pocket.16 Depending on the 
secondary structure of the isoform, the catalytic site differs 
slightly and has a direct effect on what molecules can fit into 
the site and undergo biotransformation.17 The most important 
members of the CYP family are CYP3A isoforms, especially 
CYP3A4 which is responsible for ~30% of the total hepatic 
activity of CYP.18 Other important isoenzymes highly 
engaged in drug and xenobiotic metabolism are CYP2D6 
and CYP1A2. CYP2D6 metabolizes about 20% of clinically 
relevant drugs, and its characteristic feature is a possible 
duplication of an encoding gene, which has an impact on 
the different metabolism of drugs among populations.19 
The CYP1A2 form is relevant not only in drug metabolism 
(over 10% of popular drugs) but also for polycyclic aromatic 
hydrocarbon (PAH) metabolism, leading to metabolic activa-
tion of procarcinogens.20 Products of such reactions can form 
adducts with DNA and initiate tumor development.
The problem with disturbances of CYP reactions caused 
by nanomaterials is a new topic, studied most recently on 
metallic nanoparticles (gold or silver) and using the CYP3A4 
isoform. It was shown that gold nanoparticles can inhibit the 
catalytic activity of CYPs, as well as change the expression 
of CYP genes and genes responsible for CYP regulation.21 
Ye et al also demonstrated that alterations in enzyme activity 
depend on the size of gold nanoparticles.22 Another study 
showed size-dependent inhibition of CYP enzymes for low-
toxic polystyrene nanoparticles.23 Inhibition of enzymes was 
also demonstrated for silver nanoparticles during in vitro tests, 
but not within the liver tissue of rats fed with nanoparticles.24 
As for carbon nanomaterials, mainly carbon nanotubes 
have been studied so far. Single-walled carbon nanotubes 
(SWCNT) inhibited the activity of the CYP3A4 enzyme by 
direct interaction between SWCNT and the enzyme.25 Hitoshi 
et al reported that SWCNT also downregulated genes coding 
other CYP isoenzymes, namely, CYP1A1 and CYP1B1.26
We turned our attention to other carbon nanostructures, 
such as diamond nanoparticles (DN), graphene oxide (GO) 
and graphite nanoparticles (GN), which were previously 
shown to be nontoxic or low toxic; however, no data 
are available on their potential interactions with CYP 
isoenzymes.12,14,27 We hypothesized that a physicochemical 
interaction occurs between employed carbon nanostructures 
and CYP1A2, CYP2D6 and CYP3A4 enzymes. We investi-
gated the dose-dependent effect of the nanostructures on the 
catalytic activity of CYPs using a microsome-based model 
and the influence of the carbon nanostructures on the mRNA 
expression of CYP genes and CYP-associated receptor genes 
in two hepatic-derived cell lines, HepG2 and HepaRG.
Materials and methods
Nanostructures
DN and GN powders were purchased from Skyspring 
Nanomaterials Inc. (Houston, TX, USA). Both nanoparticles 
were produced by the explosive method and synthesized 
to 3–4 nm. The purity was .95% for DN and .93% for 
GN, and the specific surface area was 282 m2/g for DN and 
540–650 m2/g for GN. Stock solutions at a concentration of 
1,000 mg/L were prepared by suspending the nanoparticles in 
ultra-pure water (MilliQ; Merck KGaA, Darmstadt, Germany) 
followed by dispersion using an ultrasonic bath at 550 W/m2 
for 1 hour (Sonorex Super RK 514H; Bandelin Electronic, 
Berlin, Germany). Stock solutions were ultrasonicated again 
for 30 minutes prior to every experiment in order to prepare 
solutions of nanoparticles. Raman spectra for the DN and GN 
used are available in the previous paper by Wierzbicki et al.28
GO was obtained from Nanopoz (Poznan, Poland), 
where it was produced by a modified Hummers’ method.29 
The obtained GO platelets had a size between 5 and 30 µm 
and contained 39%–49% of oxygen. GO was delivered in 
the form of hydrocolloid at 4,000 mg/L concentration, which 
was diluted to 1,000 mg/L. Similar to DN and GN, it was 
sonicated for 30 minutes prior to every experiment.
Visualization of nanostructures
Droplets of nanoparticle solutions at a concentration of 
50 mg/L were placed onto formvar-coated copper grids 
(Agar Scientific, Stansted, UK), and after air-drying, the grids 
were inspected by transmission electron microscopy (TEM; 
JEM-2000EX; JEOL, Tokyo, Japan) at 80 keV. Images were 
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captured with a Morada 11 megapixel camera (Olympus Soft 
Imaging Solutions GmbH, Münster, Germany).
Microsomal model with cYP450 
isoenzymes expression
Vivid® CYP450 Screening Kits with Baculosomes® 
expressing human CYP450 isoenzymes 1A2, 2D6 and 3A 
were purchased from Thermo Fisher Scientific (Waltham, 
MA, USA). Control Baculosomes lacking the expression 
of the human enzymes were purchased as a negative 
control. All reagents were handled and prepared according 
to the manufacturer’s protocol. Baculosomes system 
mimics the microsomal model for liver CYP450 enzyme 
activity studies.
Preparation of nanomaterial–cYP450 
complex for physicochemical interaction 
measurements
From the 1,000 mg/L stock solutions of DN, GO and GN, 
the following 10× concentrated solutions were prepared 
in ultra-pure water: 31.25, 62.5, 125, 250, 500 and 
1,000 mg/L. The hydrocolloids (100 µL) were then trans-
ferred to new tubes containing 800 µL of ultra-pure water 
and 100 µL of diluted Baculosomes with 1A2, 2D6 or 3A4 
expressed enzymes. Each of the Baculosomes was previously 
diluted to a concentration of 100 µg/mL of the total protein, 
according to the Baculosomes characterization specific for 
the purchased lot. Dilutions were prepared directly before 
tests. After mixing the Baculosomes with DN, GO and GN, 
the suspensions were incubated at 37°C for 1 hour and zeta 
potential, hydrodynamic diameter and adsorption of the 
enzymes to the nanostructures were measured.
Zeta potential measurements
Zeta potential of the pure hydrocolloids of DN, GO and GN 
(50 mg/L) and Baculosomes mixed with increasing concen-
trations of DN, GO and GN (complexes) were measured 
after 120 seconds of stabilization at 25°C by the microelec-
trophoretic method with Smoluchowski approximation using 
a Zetasizer Nano-ZS90 analyser (Malvern, Worcestershire, 
UK). Each measurement was repeated three times.
size distribution and hydrodynamic diameter
Size distribution and hydrodynamic diameter of the nano-
structures and the described complexes were measured using 
dynamic light scattering technique with a Zetasizer Nano-
ZS90 analyser after 120 seconds of stabilization at 25°C. 
Each measurement was repeated three times.
adsorption of cYP450 enzymes on nanostructures 
measured by free protein concentration
The quantitative effect of the adsorption of CYP450 enzymes 
expressed in the Baculosomes of DN, GO and GN was mea-
sured using the above complexes as previously described. 
Baculosomes incubated without nanostructures were used 
as a control. Additionally, the control Baculosomes without 
CYP450 expression were mixed in the same manner as the 
Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expres-
sion. After the incubation step, all tubes were centrifuged for 5 
minutes at 2,000 rpm in order to remove the heaviest complexes 
from the suspension. Free protein in Baculosomes, which was 
not adsorbed on the nanostructures, remained in the supernatant 
and was used for further analysis. Total protein content in the 
supernatant was determined using the Bicinchoninic Acid 
Protein Assay (Sigma Aldrich, St Louis, MO, USA). It is based 
on the formation of a Cu2+–protein complex under alkaline 
conditions, followed by the reduction of Cu2+ to Cu1+, which 
forms a purple complex with bicinchoninic acid. The amount 
of reduction and intensity of the purple color is proportional 
to the protein present. After adding reagents according to the 
manufacturer’s protocol, the samples were incubated for 30 
minutes at 37°C and absorbance was read at 562 nm.
enzymatic detection of cYP450 activity 
in the presence of DN, gO and gN
The assays for enzymatic activity detection were used 
according to the Vivid® CYP450 Screening Kit protocol 
for the kinetic mode. For the assays, DN, GO and GN stock 
1,000 mg/L hydrocolloids were diluted in working buffer 
from the kits (200 mM potassium phosphate, pH 8.0). Hydro-
colloids were sonicated for 30 minutes prior to dilution. The 
dilutions were 2.5× concentrated in order to obtain the follow-
ing final concentrations in the test: 3.125, 6.25, 12.5, 25, 50 
and 100 mg/L. Known inhibitors of CYP450 enzymes were 
used as positive controls: miconazole for CYP1A2, quinidine 
for CYP2D6 and ketoconazole for CYP3A4. They were 
diluted in anhydrous acetonitrile to prepare stock solutions 
and then diluted in working buffer to obtain final concentra-
tions recommended by the manufacturer in the test (30 µM 
miconazole, 10 µM quinidine and 10 µM ketoconazole).
In the first step (Figure 1), Vivid Substrates (EOMCC 
for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were 
reconstituted in anhydrous acetonitrile, and then 40 µL of 
tested compounds (DN, GO, GN or inhibitors) or working 
buffer (control) was added to each well on 96-well black-
bottom plate (Corning, New York, NY, USA). Then, 50 µL 
of Master Pre-Mix consisting of Baculosomes ( containing 
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Figure 1 a schematic representation of Baculosomes®-based enzymatic test for cYP catalytic activity measurements. 
Notes: The enzymatic reaction is initiated by the addition of a mix of NaDP+ and the proper substrate. During the reaction, the dye (blue circle) is being released from the 
substrate (blue rectangle), forming fluorescent product. Details in the main text of the “Materials and methods” section.
?????????????????????????????????????????????? ???????????????????????????????????????????? ????????????????????????????????
?????????????????????????????????????
????????????????????
????????????????????
????????????????????? ?????????????????
?????????????????????????????????
?
either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and 
NADPH reductase) in working buffer and the regeneration 
system (consisting of glucose-6-phosphate and glucose-6- 
phosphate dehydrogenase) were added to each well. The plate 
was incubated for 10 minutes to allow the compounds to inter-
act with the CYP enzymes (step 2). A pre-read of the plate 
was performed at this point in order to check for nonspecific 
fluorescence signals from DN, GO or NG. The reaction was 
initiated by addition of 10 µL Vivid Substrate and NADP+ 
mixture (step 3), and a fluorescence read was performed 
immediately in a kinetic mode at 60 seconds interval for 1 
hour with an excitation wavelength of 405 nm and an emis-
sion wavelength of 460 nm on the Infinite200 PRO microplate 
reader (Tecan Group Ltd, Männedorf, Germany). Additional 
wells containing all tested compounds and substrates without 
Baculosomes were prepared to exclude nonspecific formation 
of the fluorescent product in the presence of DN, GO and GN 
without CYP450 enzymes. All reactions were performed in 
triplicate and the experiment was run two independent times.
Inhibition of the reaction after 60 minutes was calculated 
from the following formula:
 
% inhibition
X B
A B
= −
−
−
1





 ⋅100%
 
where X=the fluorescence intensity in the presence of test 
compound, A=the fluorescence intensity in control (with-
out any inhibition) and B=the fluorescence intensity in the 
presence of the inhibitor.
cell cultures
For cytotoxicity and gene expression experiments, two 
hepatic-derived cell lines were used: HepG2 (American Type 
Culture Collection, Rockville, MD, USA) and HepaRG™ 
(Biopredic International, Saint Grégoire, France).
hepg2 cells
HepG2 cells were cultured in DMEM (Gibco™; Thermo 
Fisher Scientific) supplemented with 10% FBS (Gibco) 
and an antibiotic mix (Gibco) of penicillin (100 U/mL) and 
streptomycin (100 mg/mL), and the culture was maintained at 
37°C in a humidified atmosphere containing 5% CO
2
. HepG2 
cells were seeded at a density of 4×105 cells/mL on a 96-well 
microplate (Corning) in 100 µL of medium per well and on 
a 6-well plate in 2 mL of medium per well. The next day, 
the medium was removed and replaced with fresh medium 
containing dilutions of DN, GO and GN at concentrations 
of 3.125, 6.25, 12.5, 25, 50 and 100 mg/L on a 96-well plate 
and 50 mg/L on a 6-well plate. The dilutions were prepared 
from 10× concentrated solutions to ensure an equal volume 
of solvent (1/10) in all groups. In the control group, one-tenth 
of the medium was also replaced with the solvent (water).
heparg cells
Since HepaRG cells are terminally differentiated hepatic cells, 
they are single-use cells and prohibited from being propa-
gated. As a result, the procedure was slightly different than for 
HepG2 cells. After thawing, the cells were suspended in a base 
medium consisting of Williams’ Medium E, 1% GlutaMAX™ 
and HepaRG Supplement for Thaw, Plate and General Pur-
pose (all media from Gibco) and counted on a hemocytometer. 
Cells at a prepared density of 1.25×106 cells/mL were then 
seeded on a 12-well plate (1 mL per well) and on a 96-well 
plate (100 µL per well). Cells were cultured for 7 days 
at 37°C in a humidified atmosphere containing 5% CO
2
. 
The medium was replaced with a base medium containing 
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HepaRG  Supplement for Maintenance/Metabolism instead of 
the previous supplement on day 2 and was refreshed at days 
5 and 7. At day 8, the medium was replaced with medium 
containing DN, GO and GN at a concentration of 50 mg/L or 
medium with one tenth water in the control group.
Viability assay
In 96-well plates, cell viability was assessed after 24 hours 
of treatment with nanostructures using MTT assay, where 
yellow soluble tetrazolium salt is converted to purple for-
mazan crystals. MTT was dissolved in PBS (5 mg/mL) and 
15 µL was added per well. After 3 hours, solubilization 
detergent (10% SDS, 0.01 M HCl) was added (100 µL/well). 
Spectrophotometer readings were performed on the follow-
ing day at 570 nm on an Infinite200 PRO microplate reader 
(Tecan Group Ltd). Cell viability was expressed as the 
percentage of the control group viability, which was 100%. 
Calculations were performed from the following formula: 
ABStest/ABScontrol×100%, where “ABStest” is the absor-
bance of wells exposed to the treatment and “ABScontrol” 
is the mean absorbance of control wells.
rNa isolation
After 24 hours of treatment, cells on 6- or 12-well plates were 
removed from media. The cells were gently washed twice with 
PBS and detached from plates using cell scrapers. After col-
lecting the cells with round-bottom 2 mL tubes, the cells were 
centrifuged for 5 minutes at 1,200 rpm and the supernatant was 
replaced with freshly prepared lysis buffer from PureLink™ 
RNA Mini Kit (Thermo Fisher Scientific), which was further 
used for total RNA isolation. Cells were homogenized using 
TissueLyser LT (Qiagen, Germantown, MD, USA) with a 
pre-frosted adapter at 50 Hz for 5 minutes, followed by cen-
trifugation for 10 minutes at 1,200 rpm. The supernatant was 
transferred to new tubes and mixed with one volume of 70% 
ethanol and then transferred on a spin cartridge. Further steps 
were performed according to the manufacturer’s protocol. The 
RNA concentration in each sample after isolation was deter-
mined using the NanoDrop 2000 (Thermo Fisher Scientific).
cDNa synthesis
The RNA level in all samples was equalized, and 10 µL of 
sample was used for cDNA synthesis using the High-Capacity 
cDNA Reverse Transcription Kit (Thermo Fisher Scientific). 
The procedure was performed according to the manufactur-
er’s protocol with the following cycle conditions: 10 minutes 
at 25°C, 120 minutes at 37°C and 5 minutes at 4°C, using 
the 2720 Thermal Cycler (Thermo Fisher Scientific). cDNA 
concentration was measured with the NanoDrop 2000, and 
samples were diluted to 20 ng/µL in RNase/DNase-free 
water. Diluted and undiluted samples were kept at -20°C.
gene expression
Gene expression at the mRNA level was determined using 
the ΔΔC
T
 relative quantification real-time PCR method. 
In the experiment, the expression levels of genes for the 
previously studied cytochromes CYP1A2, CYP2D6 and 
CYP3A4, for two other cytochromes vastly expressed in the 
liver: CYP2B6 and CYP2E1, as well as the receptors respon-
sible for cytochrome gene expression regulation: pregnane X 
receptor (PXR), constitutive androstane receptor (CAR) and 
aryl hydrocarbon receptor (AhR) were measured. β-actin 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
were used as housekeeping genes. Relative gene expression 
(fold change [FC]) was calculated from the formula 2-ΔΔCT, 
where ΔΔC
T
=ΔC
T
 of a control - ΔC
T
 of a treated sample and 
ΔC
T
=mean C
T
 of β-actin and GAPDH - C
T
 of a target gene. 
The reaction was performed using the Step One™ Real-Time 
PCR System (Thermo Fisher Scientific) with the following 
settings: 95°C for 10 minutes, followed by 40 cycles of 95°C 
for 15 seconds and 60°C for 60 seconds. The reaction was 
set for 20 µL volume using 500 nM primer concentration 
(details in Table 1), Power SYBR™ Green PCR Master Mix 
(Thermo Fisher Scientific) and 50 ng of cDNA template.
statistical analysis
Data for zeta potential and hydrodynamic diameter changes 
as well as cell viability were analyzed using one-factorial 
analysis of variance with Statgraphics Centurion XVI 
(StatPoint Technologies, Warrenton, VA, USA). Differences 
between groups were tested with Tukey’s post hoc test. Data 
for gene expression were analyzed using t-tests. Differences 
at P,0.05 were considered significant.
Results
Nanostructures and cYP450–
nanostructure complexes 
physicochemical characterization
DN, GO and GN morphology inspected by TEM is presented 
in Figure 2. Zeta potential, size calculated on the basis of 
TEM pictures and the average hydrodynamic diameter mea-
sured by dynamic light scattering are presented in Table 2. 
DN and GN nanoparticles had sizes ,10 nm, while the size 
of GO platelets was ~.1 µm. The obtained results for zeta 
potential measurements, which were .25 mV for all the 
nanostructures (-25.6 mV for DN, -39.7 mV for GO and 
26.7 mV for GN) indicated the high degree of stability of 
hydrocolloids.
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Table 1 sequence of primers used in the presented study
Gene Sequence of primer 5′→3′ Amplicon 
size (bp)
Reference GenBank accession 
number
β-actin F: gaTgagaTTggcaTggcTTT
r: gTcaccTTcaccgTTccagT
102 choi et al51 NM_001101
AhR F: TaggcTcagcgTcagTTacc
r: acagTTaTccTggccTccgT
94 PrimerBlast NM_001621
CAR F: gccTcTggTcacacacTTcg
r: aTcTggTcTTcaaTgggcag
108 PrimerBlast NM_001077480
CYP1A2 F: gacaTcTTTggagcaggaTTTga
r: cTTccTcTgTaTcTcaggcTTggT
90 choi et al51 NM_000761
CYP2B6 F: agacgccTTcaaTccTgacc
r: ccTTcaccaagacaaaTccgc
105 PrimerBlast NM_000767
CYP2D6 F: ccaacggTcTcTTggacaaag
r: gggTcgTcgTacTcgaagc
79 PrimerBank ID 68509920c1
https://pga.mgh.harvard.edu/primerbank/
NM_000106
CYP2E1 F: agaccaccagcacaacTcTg
r: ccTTgaTggcagggaTTcgg
123 PrimerBlast NM_000773
CYP3A4 F: agTgTggggcTTTTaTgaTggTc
r: ccTccggTTTgTgaagacag
109 PrimerBlast NM_017460
GAPDH F: gagaaggcTggggcTcaTTTg
r: caTggTTcacacccaTgacga
97 PrimerBlast NM_002046
PXR F: acaTTgaaTgcaaTcggccc
r: gggTgTaTgTccTggaTgcg
130 PrimerBlast NM_003889
Abbreviations: DN, diamond nanoparticles; F, forward; gN, graphite nanoparticles; gO, graphene oxide; r, reverse.
Figure 2 Transmission electron microscopic images of nanoparticles. scale bar=200 nm. 
Note: (A) Diamond nanoparticles, (B) graphene oxide platelets, (C) graphite nanoparticles.
?
??????
?
??????
?
??????
Changes in the hydrodynamic diameter and zeta potential 
of microsomes (Baculosomes) incubated with increasing 
concentrations of DN, GO and GN are shown in Figure 3. 
Values for control samples of microsomes without nano-
particles (marked as 0 mg/L) differed between series, since 
they were calculated from independent measurements. 
DN almost did not affect the diameter (Figure 3A–C) or 
zeta potential (Figure 3D–F) of the microsomes expressing 
CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO 
and GN visibly increased the diameter of the microsomes, 
especially for the Baculosomes expressing CYP1A2 and 
CYP3A4 isoenzymes (.1,000 nm in comparison to ~300 nm 
in 0 mg/L samples). GN also shifted zeta potential of the 
microsomes from highly negative (-37, -31 and -42 mV 
for CYP1A2, CYP2D6 and CYP3A4, respectively) toward 
more positive values (-2, -16 and -30 mV for CYP1A2, 
CYP2D6 and CYP3A4, respectively) and GO shifted the 
values toward more negative values (-43, -44 and -48 mV 
for 1A2, 2D6 and 3A4, respectively), which indicates the 
impact of GO and GN on the stability of microsome hydro-
colloids and the occurrence of physicochemical interactions 
between the nanostructures and microsomes expressing the 
CYP enzymes. All the changes induced by GO and GN were 
concentration dependent.
The rate of the physicochemical interactions was also 
measured by the protein levels remaining in the supernatant 
after incubation of microsomes with DN, GO and GN fol-
lowed by centrifugation compared to microsomes incubated 
with solvent (ultra-pure water, MilliQ). Obtained results 
indicated that GO bound the highest amount of protein, since 
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Table 2 Physicochemical properties of the nanostructures used in the study
Nanostructure Zeta potential (mV) Size (TEM, nm) Average hydrodynamic diameter (DLS, nm)
DN -25.6 3–4 241
gO -39.7 .1,000 805
gN 26.7 2–8 318
Abbreviations: Dls, dynamic light scattering; DN, diamond nanoparticles; gN, graphite nanoparticles; gO, graphene oxide; TeM, transmission electron microscopy.
Figure 3 changes in hydrodynamic diameter (A–C) and zeta potential (D–F) of microsomes expressing individually different isoenzymes of cytochrome P450 after 
incubation with increasing concentrations of the carbon nanostructures. 
Notes: DN – green circles, gO – blue squares, gN – yellow triangles. Measurements were performed after 1 hour of incubation of the nanostructures with microsomes 
at 37°c. Incubation with microsomes expressing cYP1a2 (A, D), cYP2D6 (B, E) and cYP3a4 (C, F). results presented as means (n=3) with SD. *Statistical significance 
between the concentration and control measurements of microsome without nanostructures (P,0.05, one-factorial analysis of variance with Tukey’s posttest). 
Abbreviations: DN, diamond nanoparticles; gO, graphene oxide; gN, graphite nanoparticles.
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only about 50% of the protein remained in the supernatant. 
However, additional measurements performed with the 
control Baculosomes, which did not express any recombi-
nant CYP isoenzyme, revealed that the binding might not 
be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, 
since a similar decrease in the protein level was observed 
(Table 3).
enzymatic activity of cYP450 in the 
presence of nanostructures
In the enzymatic test based on Baculosomes, all three types 
of nanostructures inhibited reactions by CYP1A2, CYP2D6 
and CYP3A4 isoenzymes. Inhibition rate was compared to 
inhibition in positive control samples with the known spe-
cific inhibitors miconazole, quinidine and ketoconazole for 
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Table 3 cYP proteins adsorption on DN, gO and gN measured by the amount of free protein remaining in the supernatant after 
incubation with the nanostructures
Nanostructure Free protein (% of protein in samples without nanostructures)
CYP1A2 CYP2D6 CYP3A4 Control Baculosomes®
DN 92.8±1.15 80.7±2.19 75.2±7.37 80.8±1.02
gO 47.3±0.12 53.5±0.99 54.9±1.09 48.9±0.37
gN 104.8±0.68 85.6±0.94 84.9±2.13 91.2±3.96
Notes: results presented as relative values as % of the protein in samples incubated without nanostructures, means from three replicates with sDs. control Baculosomes 
are microsomes obtained from cells which were not transfected with human cYP genes. Thus, they do not express any of the studied isoenzymes and sustain, at the same 
time, the structure is typical for other microsomes.
Abbreviations: DN, diamond nanoparticles; gN, graphite nanoparticles; gO, graphene oxide.
Product formation in the presence of nanostructures
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Figure 4 Fluorescent product formation by individual cytochrome P450 in time in the presence of increasing concentration of carbon nanostructures. 
Notes: DN (A–C), gO (D–F) and gN (G–I). catalytic activity of cYP1a2 (A, D, G), cYP2D6 (B, E, H) and cYP3a4 (C, F, I). Measurements were performed immediately 
after adding specific substrates with 60-second intervals for 1 hour. Values plotted on the graphs are means calculated from three wells for each timepoint. The green line 
depicts control without the nanostructures (reaction not disturbed), and the red line depicts inhibitor control (30 µM miconazole for cYP1a2, 10 µM quinidine for cYP2D6 
and 10 µM ketoconazole for cYP3a4). 
Abbreviations: DN, diamond nanoparticles; GO, graphene oxide; GN, graphite nanoparticles; RFU, relative fluorescence units.
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Figure 5 The relative inhibition of cYP1a2 (A), cYP2D6 (B) and cYP3a4 (C) enzymes after 1 hour of incubation with increasing concentrations of carbon nanostructures. 
Notes: DN (black bars), gO (light gray bars) and gN (dark gray bars). rate of inhibition is presented as relative % value calculated in comparison to the control and the 
specific inhibitor from the formula: % inhibition = [1-(x-b/a-b)] ×100%, where x is the fluorescence intensity in the presence of test compound, a the fluorescence intensity 
in control and b the fluorescence intensity in the presence of inhibitor. 
Abbreviations: DN, diamond nanoparticles; gO, graphene oxide; gN, graphite nanoparticles.
CYP1A2, CYP2D6 and CYP3A4, respectively. Cytochrome 
enzymatic activity was not completely inhibited by nano-
structures; however, the rate of the reaction and fluorescent 
product formation was significantly lower (Figure 4) for all 
the nanostructures. The degree of inhibition was different 
between the nanostructures and the isoenzymes (Figure 5). 
In the reaction catalyzed by CYP1A2, higher inhibition at a 
similar level was observed for DN and GN (about 70%–80% 
compared to the control inhibitor, miconazole) than for 
GO (20%–50% inhibition). In the DN and GN groups, the 
highest concentration (100 mg/L) inhibited the reaction less 
than lower concentrations, whereas in GO, we observed 
the opposite effect – the rate of inhibition was concentra-
tion dependent in this case. The inhibition rate of CYP3A4 
was comparable for DN, GO and GN at all concentrations 
(50%–60% inhibition); however, at the highest concentra-
tion, we observed an effect similar to the one in CYP1A2.
cell viability and cYP450 gene 
expression in hepatic-derived cell lines
The tested nanostructures did not induce significant toxic 
effect in cells. No cytotoxic effect was observed for DN 
in HepG2 cell line at any of the introduced concentrations, 
while for GO, viability was slightly decreased at 50 and 
100 mg/L concentrations (Figure 6A). In the GN group, 
viability was decreased by about 50% in concentrations 
from 25 to 100 mg/L. In the HepaRG cells, where 50 mg/L 
concentration was selected for the test, no cytotoxic effect 
was observed for DN, GO and GN (Figure 6B).
To obtain more reliable results, changes in gene expres-
sion were calculated in relation to two housekeeping genes, 
β-actin and GAPDH. The results are presented as log
2
 
(FC) for convenient interpretation of positive and negative 
regulation of expression in comparison to 0=no regulation 
in the control group (Figure 7). Detailed calculated FCs and 
classification of gene regulations are summarized in Table 4. 
Genes coding CYP450 isoenzymes (Figure 7A–C) as well as 
genes coding CYP450-related receptors (Figure 7B–D) were 
mostly downregulated at the mRNA level and the effect was 
stronger in the HepaRG cell line than in the HepG2 cell line. 
GO had the highest impact on studied gene expression, which 
was visible for the HepaRG line. CYP1A2 expression was sig-
nificantly decreased in both cell lines in the DN (45.9% and 
36% of the control in HepG2 and HepaRG, respectively) and 
GO (50.6% and 1.7% of the control in HepG2 and HepaRG, 
respectively) groups, but increased in the GN group (55.8% 
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Figure 6 (A) hepg2 and (B) heparg cell viability after treatment with increasing concentrations of carbon nanostructures. 
Notes: DN (black bars), gO (light gray bars) and gN (dark gray bars). cell viability was determined by MTT assay. results are presented as means with sD (n=3) as a % 
of control, containing only solvent in the same volume as in nanostructure-treated wells. *Statistical significance in comparison to control (P,0.05, one-factorial analysis of 
variance with Tukey’s posttest).
Abbreviations: DN, diamond nanoparticles; gO, graphene oxide; gN, graphite nanoparticles.
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Figure 7 real-time Pcr analysis of cYP genes (A, C) and cYP-related receptor genes (B, D) at the mrNa level in hepg2 (A, B) and heparg (C, D) cells after 24 hours 
treatment with carbon nanostructures at a concentration of 50 mg/l. 
Notes: DN (black bars), gO (light gray bars) and gN (dark gray bars). Bars represents means with sD (n=3, each of the biological replicates run in two technical replicates). 
relative expression was calculated using two housekeeping genes, β-actin and GAPDH. results are presented as log2 Fc for easier interpretation of up- and downregulation 
and the scale of regulation in comparison to the gene expression in untreated cells, depicted as 0. Positive values: upregulation, negative values: downregulation. *statistically 
significant difference in comparison to untreated cells (P,0.05, t-test). **P,0.01; ***P,0.001.
Abbreviations: DN, diamond nanoparticles; Fc, fold change; gO, graphene oxide; gN, graphite nanoparticles.
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Table 4 changes in the expression of cytochrome P450 (cYP) enzymes and their regulatory receptors in hepg2 and heparg cells 
by real-time Pcr
Cell line HepG2 HepaRG
Treatment Classification Gene FC Log2 FC Classification Gene FC Log2 FC
DN
Upregulated
CYP2B6 2.137 1.095 Upregulated CYP2D6 1.351 0.434
CYP2D6 1.584 0.664
Downregulated
CYP1A2 0.364 -1.457
CYP2E1 1.542 0.624 CYP2B6 0.524 -0.931
PXR 1.498 0.583 CYP2E1 0.994 -0.001
Downregulated
CYP1A2 0.459 -1.125 CYP3A4 0.264 -1.923
CYP3A4 0.311 -1.684 AhR 0.721 -0.471
AhR 0.850 -0.233 CAR 0.596 -0.748
CAR 0.852 -0.234 PXR 0.701 -0.513
gO
Upregulated
CYP2B6 2.546 1.348
Downregulated
CYP1A2 0.017 -5.876
CYP2D6 1.116 0.159 CYP2B6 0.042 -4.557
PXR 1.117 0.160 CYP2D6 0.963 -0.005
Downregulated
CYP1A2 0.506 -0.982 CYP2E1 0.011 -6.538
CYP2E1 0.761 -0.394 CYP3A4 0.010 -6.660
CYP3A4 0.441 -1.182 AhR 0.330 -1.598
AhR 0.446 -1.164 CAR 0.022 -5.516
CAR 0.762 -0.392 PXR 0.182 -2.461
gN
Upregulated
CYP1A2 1.558 0.640
Upregulated
CYP1A2 2.387 1.255
CYP2B6 1.339 0.421 CYP2D6 1.264 0.337
CYP2D6 1.186 0.246 CYP3A4 1.066 0.092
Downregulated
CYP2E1 0.905 -0.144 PXR 1.040 0.056
CYP3A4 0.202 -2.310
Downregulated
CYP2B6 0.818 -0.291
AhR 0.897 -0.158 CYP2E1 0.528 -0.921
CAR 0.819 -0.289 AhR 0.678 -0.560
PXR 0.343 -1.54 CAR 0.638 -0.649
Abbreviations: DN, diamond nanoparticles; Fc, fold change; gN, graphite nanoparticles; gO, graphene oxide.
and 138.7% more than in the control, HepG2 and HepaRG, 
respectively). No significant changes were observed for 
CYP2D6; however, in other studied members of the CYP2 
subfamily (2B6 and 2E1), we observed lower expression of 
both genes in HepaRG cells, while in HepG2 cells, the 2B6 
level was increased. The level of CYP3A4 was decreased 
in all nanostructure groups in both cell lines (,40% of the 
control, reaching only 1% in the GO group in HepaRG cells), 
except the GN group in HepaRG cells, where no changes 
occurred. For AhR, CAR and PXR genes, we observed 
decrease of gene expression in all groups in the HepaRG 
cell line (2.2%–72.1% of the control) and similar, but less 
significant, effect in the HepG2 cell line (31.1%–89.7% of 
the control). Upregulation was noted only for PXR in the 
DN group in HepG2 cells (49.8% more than in the control).
Discussion
In this study, we presented interactions among three nano-
structures of different carbon allotropes, namely, DN, GO 
and GN, and isoenzymes of CYP450, namely, CYP1A2, 
CYP2D6 and CYP3A4, in the model of Baculosomes. 
We also demonstrated the consequences of the interactions 
that occurred, resulting in inhibition of enzymatic activity of 
CYP450, as well as the effect of introduction of DN, GO and 
GN to hepatic-derived cells of HepG2 and HepaRG cell lines, 
resulting in downregulation of CYP450 and CYP-related 
genes at the mRNA level.
Using microsome-based Baculosomes model (here 
referred to as microsomes) incubated with the nanostruc-
tures, we demonstrated that GO and GN interacted with 
CYP450 in a dose-dependent manner, increasing the average 
hydrodynamic diameter of the microsomes and changing 
their zeta potential. Shifting values of the potential toward 
higher values in the case of GN and toward more negative 
values in the group with GO could be related to the zeta 
potential of bare nanostructures (-39.7 mV for GO and 
26.7 mV for GN). Since DN has similar zeta potential to the 
microsomes (~-30 mV), such shifting was not observed. 
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Highly positive potential of GN could also directly enhance 
the binding between GN and the microsomes, increasing the 
hydrodynamic diameter. As DN did not affect either of the 
parameters, the interactions can be also related to differences 
in structure at the atomic level as well. Although DN usually 
has on its surface sp2-hybridized carbon atoms and graphitic 
areas to some extent, sp3 hybridization is typical for most of 
the atoms, building the characteristic core of DN and making 
DN one of the most inert materials.30 Typical for GO and GN, 
sp2 hybridization and the presence of π electrons might be 
responsible for the interactions, which are discussed below. 
Measurements of the level of protein adsorption at the nano-
structures revealed that microsomes binding to the nanostruc-
tures might be nonspecific to the CYP isoenzyme type and 
connected with the structure of the microsome itself, meaning 
also phospholipid membranes (structurally, the microsomes 
are phospholipid spheres expressing transmembrane CYP 
proteins). It is still important because any microsome-based 
model represents hepatocyte endoplasmic reticulum (inter-
nal phospholipid membranes) containing all the necessary 
compounds for the catalytic activity of CYP450 and trans-
membrane protein CYP450 cannot be studied separately from 
cellular membranes. Therefore, it is still the preferred model 
for preclinical studies of drug metabolism mechanisms.31
The most important evidence for the direct interaction 
between CYP-expressing microsomes and DN, GO and GN 
is inhibition of the catalytic activity of CYP1A2, CYP2D6 
and CYP3A4 measured separately for all three isoforms 
and revealing subtle differences among the isoenzymes. 
Product formation on CYP1A2 was highly inhibited by DN 
and GN, while on CYP2D6 and CYP3A4, all nanostructures 
inhibited the reaction at similar levels. Interestingly, inhibi-
tion of CYP1A2 and CYP3A4 was lower in the presence 
of the highest concentration of DN and GN (100 mg/L), 
which could be related to the formation of nanoparticle 
agglomerates in higher concentrations and then reduction 
of their surface area available to interact.32 When lower 
concentrations were introduced, the nanoparticles were prob-
ably more dispersed and, taking into consideration the size 
of the smallest nanoparticles (2–4 nm), they could better fit 
into the canal leading to the active site of the enzyme. On the 
contrary, inhibition of CYP1A2 was concentration dependent 
in the presence of GO. Another important deduction from 
the course of the reaction was disturbances occurring on all 
of the cytochromes in the presence of GO. In our studies, 
a direct redox reaction between GO and the substrates was 
excluded by running independent samples without CYP 
enzymes. It has been reported previously that GO has an 
exceptionally high capability of spontaneously binding to 
proteins33 and other macromolecules,34 and it depends on the 
number of oxide-containing groups on the surface.35 Thus, 
it is probable that GO bound the substrate or prevented the 
substrate from entering the active site of CYP by binding to 
microsomes. Using the molecular dynamics method, it was 
previously demonstrated that multi-walled carbon nanotubes 
can bind competitively to a protein, preventing the specific 
ligand from binding.36
DN, GO and GN were previously demonstrated to be 
biocompatible nanomaterials with no significant toxic effect 
within an organism.14 Results for viability assessment of 
HepG2 and HepaRG cells in the present study confirmed 
that DN has no direct cytotoxic effect for hepatic-derived 
cells in the in vitro conditions and GO almost had no impact, 
whereas GN decreased HepG2 cell viability in concentrations 
higher than 25 mg/L. Even though no direct toxic effect 
was observed, carbon nanostructures can still affect the 
molecular pathways within cells.28 Downregulation of CYP-
coding genes and CYP-related receptor genes in HepG2 and 
HepaRG cells in the presence of DN, GO and GN confirmed 
this statement. General downregulation of the genes was 
especially visible in HepaRG cells, which probably results 
from a weaker expression of genes encoding enzymes of 
Phases I and II of the xenobiotic metabolism in the HepG2 
cell line, making HepaRG a more suitable model for drug 
metabolism studies.37–39
The strongest downregulation of CYP genes was induced 
by GO, which influenced not only CYP1A2 and CYP3A4 
genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, 
which are responsive elements regulating the expression of 
CYP genes.17 This indicates that GO not only directly inhibits 
CYP isoenzymes itself but also attenuates the expression of 
mRNA, which may lead to reduction of the protein pool, 
limiting the enzymes available to run reactions. Lammel et al 
reported that GO itself did not change the mRNA expres-
sion of CyP1A in PLHC-1 cells from topminnow fish, but 
could enhance the transport of AhR to the nucleus.40 In other 
studies by Hitoshi et al, multi-walled carbon nanotubes 
downregulated CYP1A1 and in HepG2 cells by repression 
of AhR binding to the enhancer region.26 Interestingly, we 
observed induction of CYP1A2 upon treatment with GN. 
A known inducer of CYP1A2 is cigarette smoke containing 
a significant amount of nanoparticulated carbon black and 
PAH.17,41 Thus, it might be related to GN structure, more 
similar to compounds found in the cigarette smoke, when 
compared to the DN or GO used in this study, as PAH 
structure also consists of sp2-hybridized carbon atoms with 
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delocalized π electrons, which is a reason for naming PAH 
nanographenes or cutouts of graphene.42
The enzymes belonging to the CYP450 family are some 
of the most important enzymes within hepatocytes, as they 
are responsible for the initial phase of xenobiotic degradation, 
drug metabolism and prodrug activation.18 If they are affected 
in the discussed way, relevant changes in xenobiotic metabo-
lism may occur. Examples of implications for applications in 
the medical field are a disturbance in drug clearance or inhibi-
tion of active drug formation from a prodrug, leading either 
to intoxication of an organism or diminishing the expected 
effect of the drug.43 It is important when considering DN, GO 
or GN for drug-delivery systems and in the case of in vivo 
introduction; yet, it should be noted that such interactions may 
affect the metabolism of xenobiotics in general. Particularly, 
it is known that DN, GO or GN remain within an organism 
after administration and have a tendency to be transported and 
stored in liver tissues (summarized by Kurantowicz et al).13 
Bare nanostructures within the bloodstream usually undergo 
so-called protein corona formation with blood plasma 
proteins, which prevents them from interacting with other 
molecules; however, when they are internalized in cells, 
the corona is degraded again in the lysosomes.44 This may 
lead to direct physicochemical interaction of nanostructures 
with internal membranes and proteins within liver cells. The 
interactions may induce changes in a protein conformation45 
or block an active site in an enzyme.25
It was previously reported that SWCNT inhibited the most 
important of the isoenzymes, CYP3A4, mostly due to the 
occurrence of π–π stacking interactions between the nanotube 
walls and aromatic residues of the enzyme.25 A carbon nano-
tube is, in fact, a rolled sheet of graphene, which is a single 
atomic layer of crystalline graphite; therefore, its surface 
consists of the same hexagonally arranged carbon atoms at sp2 
hybridization with π electrons.46 Thus, it can be expected that 
graphite and graphene interact with CYP similar to SWCNT, 
since graphene and its derivatives have similar, yet much higher 
due to the difference in curvature, capacities for disrupting 
protein structure.47 In the case of GO, which is an oxidized 
form of graphene, such interactions might not play such an 
important role, since π electrons are diminished because of 
the introduction of oxide-containing groups. Oxide-containing 
groups and defect sites in graphene or GO may also interact 
by an electrostatic interaction with a hydrogenated group 
in a protein.36 Moreover, inside a cell, GO can be degraded 
similarly to nanotubes by enzymes belonging to peroxidases, 
which creates holes by binding to the graphitic surface 
of GO, resulting in more defects prone to the interactions.33,48–50
Conclusion
We have demonstrated that DN, GO and GN inhibit the 
catalytic activity of CYP450 1A2, 2D6 and 3A4 isoenzymes 
and downregulate the expression of CYP-coding genes and 
CYP-related genes at the mRNA level, with special emphasis 
on GO. The results showed that even though carbon nano-
structures do not induce cytotoxic effects in liver-derived 
cells, they impact molecular pathways. The consequence 
of the interactions may include interruptions in drug and 
xenobiotic metabolism, which is especially important due to 
future in vivo applications.
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